Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07348237 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
A Phase 1 study of End Stage Renal Disease and Renal Impairment, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT07348237: Recruiting Phase 1 study of End Stage Renal Disease and Renal Impairment, sponsored by Merck Sharp & Dohme.
NCT07348237 is a Phase 1 study of End Stage Renal Disease and Renal Impairment that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 24 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07348237, a Phase 1 study of End Stage Renal Disease and Renal Impairment, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.
Primary Outcome
Blood samples will be collected to determine the AUC0-inf of MK-2828
Conditions Studied
Interventions
- DRUG MK-2828
Study Locations (3)
Florida
- Panax Clinical Research ( Site 0003) - Miami Lakes
- Floridian Clinical Research ( Site 0001) - Miami Lakes
- Orlando Clinical Research Center ( Site 0002) - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2026-08-18 |
| Phase | Phase 1 |
What NCT07348237 shows while recruiting
NCT07348237 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which MK-2828 is the first listed.
NCT07348237 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07348237 about?
NCT07348237 is a clinical study titled "A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)". The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.
What is the current status of trial NCT07348237?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2026-03-02. Estimated completion is 2026-08-18.
What conditions does trial NCT07348237 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Renal Impairment, Chronic Kidney Failure.
What interventions are being tested in trial NCT07348237?
The interventions under investigation include: MK-2828 (DRUG).
Who is sponsoring clinical trial NCT07348237?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07348237 being conducted?
This trial has 3 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07348237's enrollment target sits among peer trials
24 67th of 86 higher than 20 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
-
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
COMPLETED · Phase 1
-
Plazomicin Study in ESRD Patients Receiving IHD
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
COMPLETED · Phase 1
-
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI